Author’s response to reviews

Title: Mucopolysaccharidosis Type VI: Case Report with First Neonatal Presentation with Ascites Fetalis and Rapidly Progressive Cardiac Manifestation

Authors:

Rachel Honjo (rachel.honjo@hc.fm.usp.br)
Evelyn Nuñez Vaca (cristinanunezvaca@gmail.com)
Gabriela Leal (gnleal@gmail.com)
Deipara Abellan (deipara.abellan@hc.fm.usp.br)
Nana Ikari (nana.miura@hc.fm.usp.br)
Marcelo Jatene (marcelo.jatene@hc.fm.usp.br)
Ana Martins (ni.martins10@gmail.com)
Chong Kim (chong.kim@hc.fm.usp.br)

Version: 2 Date: 02 Dec 2019

Author’s response to reviews:

São Paulo, SP, BRAZIL

December 2nd, 2019

Dear Editorial Board of BMC Medical Genetics,

I would like to thank the opportunity to review and re-submit our case report.

Please find below the answers to the Editor comments of the manuscript “Mucopolysaccharidosis Type VI: Presentation with Ascites Fetalis and Rapidly Progressive Cardiac Manifestation”.

Assistant Editor Comments:

1. Remove attachments
Please remove the additional file entitled ‘CARE Guidelines Case Report MPS VI0001.pdf’ from your manuscript and from the file inventory as it is no longer needed at this stage.

ANSWER: The file was removed.

2. Ethics approval and consent to participate

Please amend the following statement in the ‘Ethics approval and consent to participate’ section of your manuscript: “The patient’s legal guardians (parents) have signed informed consent to participate in this study and consented to publish this case report, including medical data and images” to “The patient’s legal guardians (parents) have signed informed consent to participate in this study”.

ANSWER: This statement was already included in the last version of the manuscript.

3. Consent for publication

Please amend the following statement in the ‘Consent for publication’ section of your manuscript: “The patient’s legal guardians (parents) have signed informed consent to participate in this study and consented to publish this case report, including medical data and images” to “The patient’s legal guardians (parents) have provided written consent to publish this case report, including medical data and images”.

ANSWER: This statement was already included in the last version of the manuscript.

4. Competing interests

a) Currently, your competing interests statement is unclear.

Please note that a competing interest exists when the authors’ interpretation of data or presentation of information may be influenced by, or may be perceived to be influenced by, their personal or financial relationship with other people or organizations. Competing interests may be financial or non-financial. Authors should disclose any financial competing interests but also any non-financial competing interests that may cause them embarrassment if they were to become public after the publication of the manuscript.

If the authors have no competing interests, please include the statement “The authors declare that they have no competing interests” in the Competing interests section of your manuscript.

ANSWER: The statement “The authors declare that they have no competing interests” was included in the Competing interests section of the manuscript.
b) Please do not remove the statement “The authors received financial support for the payment of the fee publication by BioMarin Pharmaceutical Inc.” from the Competing Interests section of your manuscript.

ANSWER: The statement was not removed.

4. Role of funding body

Please provide more details regarding the specific role of the funding body in your study. If the funding body only provided the financial means to allow the authors to carry out the study, please state “The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript” and include this statement in the Funding section of your manuscript.

However, if the funding body took part in the design of the study and collection, analysis, and interpretation of data, and the writing of the manuscript, this must be stated in the Competing Interests section of your manuscript.

ANSWER: The statement “The funding body played no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript” was included in the Funding section of the manuscript.

5. Availability of data and materials

Please note that BMC mandates data deposition for the following:

- Protein sequences
- DNA and RNA sequences
- DNA and RNA sequencing data
- Genetic polymorphisms
- Linked genotype and phenotype data
- Macromolecular structure
- Microarray data (must be MIAME compliant)
- Crystallographic data for small molecules

Seeing as this applies to your study, we ask that you please provide the relevant accession numbers if your data has been deposited into a data bank or the appropriate web links if the data
has been uploaded into a repository. If the data has not yet been deposited, please do so and provide the relevant information needed to access it in the ‘Availability of data and materials’ section in your manuscript. Please ensure all data is already released and that any accession numbers/web links are in the ‘Availability of Data and Materials’ in their final form, and that all links and accessions allow access to public data.

Your data availability statement can take the following form: “The datasets generated and/or analysed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK OR ACCESSION NUMBER TO DATASETS].”

ANSWER: The biochemical and molecular investigations were performed in an external laboratory and we do not have access to the data banks.

6. Author contributions

Please clarify whether all of the authors of this manuscript have read and approved the final manuscript in the Authors’ contributions section of your manuscript.

If so, please include the statement “All authors read and approved the final manuscript.” in the Authors’ contributions section of your manuscript.

ANSWER: The statement was added in the Authors’ section.

7. At this stage, please upload your manuscript as a single, final, clean version that does not contain any tracked changes, comments, highlights, strikethroughs or text in different colours. All relevant tables/figures/additional files should also be clean versions. Should you wish to respond to these revision requests, please put your responses to the reviewers’/editors’ comments in the Response to Reviewers box in Editorial Manager. Please do not upload a separate letter.

ANSWER: The text was modified as to delete comments and accepted previous modifications.

**Please also complete the minor revisions requested in Reviewer Reports section below.

Reviewer reports:

Eirini Manoli (Reviewer 1):

The authors provided clarifications to several questions raised by the reviewer and successfully edited the corresponding sections of the manuscript.

ANSWER: The references were added to the manuscript. We added a last sentence to the text in order to reference the two articles: “This can be an extremely valuable diagnostic clue to an early diagnosis so that specific therapy and management can be implemented”.

Sincerely yours,

Rachel Sayuri Honjo on behalf of the authors

Corresponding author:
Rachel Sayuri Honjo, M.D., Ph.D.
Unidade de Genética do Instituto da Criança – HCFMUSP
Av. Dr. Enéas Carvalho de Aguiar, 647
São Paulo – SP – Brazil
CEP 05403-000
Email: rachel.honjo@hc.fm.usp.br
Telephone: +55 (11) 2661-8671